

# Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy

Moroi, Alyssa J.; Watson, Steve P.

DOI:

[10.1016/j.bcp.2015.02.004](https://doi.org/10.1016/j.bcp.2015.02.004)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Moroi, AJ & Watson, SP 2015, 'Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy', *Biochemical Pharmacology*, vol. 94, no. 3, pp. 186-194. <https://doi.org/10.1016/j.bcp.2015.02.004>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

NOTICE: this is the author's version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Moroi AJ, Watson SP, Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: haemostasis, platelet activation and antithrombotic therapy, *Biochemical Pharmacology* (2015), <http://dx.doi.org/10.1016/j.bcp.2015.02.004>

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Accepted Manuscript

Title: Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis, platelet activation and antithrombotic therapy

Author: Alyssa J. Moroi Steve P. Watson



PII: S0006-2952(15)00108-2  
DOI: <http://dx.doi.org/doi:10.1016/j.bcp.2015.02.004>  
Reference: BCP 12190

To appear in: *BCP*

Received date: 3-11-2014  
Revised date: 9-2-2015  
Accepted date: 9-2-2015

Please cite this article as: Moroi AJ, Watson SP, Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: haemostasis, platelet activation and antithrombotic therapy, *Biochemical Pharmacology* (2015), <http://dx.doi.org/10.1016/j.bcp.2015.02.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1  
2  
3  
4  
5  
6  
7  
8  
9 **Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM**  
10 **receptors: haemostasis, platelet activation and antithrombotic therapy**  
11  
12  
13

14 Authors: Alyssa J. Moroi and Steve P. Watson  
15  
16

17 Corresponding Author: Alyssa J. Moroi  
18  
19

20  
21 Centre for Cardiovascular Sciences, Institute for Biomedical Research, The College of  
22  
23 Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United  
24  
25 Kingdom  
26  
27

28  
29 E-mail: Alyssa Moroi <A.J.Moroi@bham.ac.uk>  
30  
31

32  
33 TEL: +44 (0) 121 414 2560  
34  
35  
36  
37  
38

39 **ABSTRACT**  
40  
41

42 Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that are activated in  
43  
44 response to various stimulants, and they regulate many processes including inflammation;  
45  
46 the stress response; gene transcription; and cell proliferation, differentiation, and death.  
47  
48

49 Increasing reports have shown that the PI3Ks and their downstream effector Akt are  
50  
51 activated by several platelet receptors that regulate platelet activation and haemostasis.  
52  
53

54 Platelets express two immunoreceptor tyrosine based activation motif (ITAM) receptors,  
55  
56 collagen receptor glycoprotein VI (GPVI) and Fc $\gamma$  receptor IIA (Fc $\gamma$ RIIA), which are  
57  
58 characterized by two YxxL sequences separated by 6–12 amino acids. Activation of an  
59  
60  
61  
62

1  
2  
3  
4  
5  
6  
7 ITAM receptor initiates a reaction cascade via its YxxL sequence in which signaling  
8  
9 molecules such as spleen tyrosine kinase (Syk), linker for activation of T cells (LAT) and  
10  
11 phospholipase C  $\gamma$ 2 (PLC $\gamma$ 2) become activated, leading to platelet activation. Platelets also  
12  
13 express another receptor, C-type lectin 2 (CLEC-2), which has a single YxxL sequence, so  
14  
15 it is appropriately called a hemITAM receptor. ITAM receptors and the hemITAM receptor  
16  
17 share many signaling features. Here we will summarize our current knowledge about how  
18  
19 the PI3K/Akt pathway regulates (hem)ITAM receptor-mediated platelet activation and  
20  
21 haemostasis and discuss the possible benefits of targeting PI3K/Akt as an antithrombotic  
22  
23 therapy.  
24  
25  
26  
27  
28  
29  
30

### 31 **Abbreviation**

32  
33 PI3K, phosphoinositide 3-kinases; ITAM, immunoreceptor tyrosine based activation motif;  
34  
35 GPVI, glycoprotein VI; Fc $\gamma$ RIIA, Fc $\gamma$  receptor IIA; Syk, spleen tyrosine kinase; LAT,  
36  
37 linker for activation of T cells; PLC $\gamma$ 2, phospholipase C gamma 2; CLEC-2, C-type lectin;  
38  
39 vWF, von Willebrand factor; TxA<sub>2</sub>, thromboxane A<sub>2</sub>; GPCR, G protein-coupled receptor;  
40  
41 TCR, T cell receptor; Lck, leukocyte-specific kinase; Zap-70, zeta-chain-associated protein  
42  
43 kinase 70; CRP, collagen-related peptides; HEV, high endothelial venule; Grb2, growth  
44  
45 factor receptor-bound protein-2; Gads, growth factor receptor-bound protein-2 adaptor  
46  
47 downstream of Shc; PTEN, phosphatase and tensin homologue deleted on chromosome 10;  
48  
49 DAG, diacyl glycerol; SHIP, SH2 domain-containing inositol polyphosphatase; PKC,  
50  
51 protein kinase C; CaMKK, Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinase; SNP, single-  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 nucleotide polymorphism; GSK3, glycogen synthase kinase 3; LiCl, lithium chloride; MEK,  
8  
9 MAPK/ERK kinase; ERK, extracellular signal-regulated kinase

## 10 11 12 13 14 **Keywords**

15  
16 Protein kinase B; Phosphatidylinositol 3-kinases; Platelets; C-type lectin; Glycoprotein VI

## 17 18 19 20 21 **1. Introduction**

22  
23 Platelets are released from megakaryocytes in the bone marrow and have a short life,  
24  
25 circulating in blood for about 9–10 days. Because they are fragments of megakaryocytes,  
26  
27 they have no nucleus. Platelet activation is a vital step in both haemostasis: a physiological  
28  
29 response that prevents significant blood loss following vascular injury and thrombosis: a  
30  
31 pathological extension of normal haemostasis [1]. Platelets circulate in healthy vessels, but  
32  
33 when a vessel wall is damaged, platelets become activated when they interact with the  
34  
35 newly exposed subendothelial collagen. Platelets are tethered onto the site of injury through  
36  
37 interaction of the glycoprotein (GP) Ib-V-IX complex with von Willebrand factor (vWF),  
38  
39 which is bound to exposed collagen. This interaction enables collagen to interact with  
40  
41 glycoprotein (GP) VI, thus initiating signaling events that lead to the conformational  
42  
43 change (activation) of integrins  $\alpha$ IIb $\beta$ 3 and  $\alpha$ 2 $\beta$ 1, enabling the former to bind to vWF and  
44  
45 fibrinogen and the latter to bind to collagen. Following activation of these receptors,  
46  
47 secondary mediators such as ADP and thromboxane A<sub>2</sub> (TxA<sub>2</sub>) are secreted from platelets  
48  
49 and activate ADP receptors and TxA<sub>2</sub> receptors, further supporting the haemostatic and  
50  
51 thrombotic function of platelets. Dysregulation or dysfunction of platelet signaling events  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 can lead to bleeding disorders or formation of arterial thrombosis; thus it is important to  
8  
9 understand platelet signaling pathways so we can treat these disorders appropriately [1].  
10  
11 PI3K and its downstream effectors are activated by several platelet receptors, however  
12  
13 inhibition of PI3K isoforms or their downstream effectors leads to only partial blockade of  
14  
15 platelet activation and only has a significant effect in response to low agonist  
16  
17 concentrations [1-3]. This characteristic therefore makes them very attractive targets for  
18  
19 novel antithrombotic therapy reducing the risk of potential bleeding side effects, which  
20  
21 current strategies have to negotiate.  
22  
23  
24  
25  
26  
27

## 28 **2. Platelet receptors**

29  
30 Platelets are known to express a wide variety of receptors: G protein-coupled receptors  
31  
32 (GPCRs) (thrombin receptors PAR-1 and PAR-4), integrins ( $\alpha$ Ib $\beta$ 3,  $\alpha$ 2 $\beta$ 1,  $\alpha$ 5 $\beta$ 1,  $\alpha$ 6 $\beta$ 1,  
33  
34  $\alpha$ v $\beta$ 3), leucine-rich repeat (LRR) family receptors (GPIb/IX/V), ADP receptors (P2Y<sub>1</sub> and  
35  
36 P2Y<sub>12</sub>), TxA<sub>2</sub> receptors (TP $\alpha$  and TP $\beta$ ), immunoglobulin superfamily receptors (GPVI,  
37  
38 Fc $\gamma$ RIIA), and C-type lectin-like receptors (P-selectin and CLEC-2) [4] (Table1). Many of  
39  
40 these receptors have had their signaling mechanisms investigated with data suggesting they  
41  
42 share a high degree of similarity with the receptors activated under growth factors or  
43  
44 hormones in nucleated cells. The common signaling pathways are activation of  
45  
46 phospholipase C (PLC) and elevation of intracellular Ca<sup>2+</sup>, leading to secretion of  
47  
48 secondary mediators to facilitate platelet activation and conversion of inactive integrin via a  
49  
50 conformational change to its ligand-binding active state (inside-out signaling). Among  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 these signaling events, phosphoinositide signaling is active in platelets and has been shown  
8  
9 to play a critical role in platelet activation [1].  
10

### 11 **3. Platelet ITAM receptors**

12  
13 The immunoreceptor tyrosine based activation motif (ITAM) is a highly conserved  
14  
15 sequence defined by  $Y_{xx}(L/I)_{x_{6-12}}Y_{xx}(L/I)$  which can be found in the cytosolic domain in a  
16  
17 number of receptors and adaptor proteins. When phosphorylated, ITAMs serve as docking  
18  
19 sites for SH2 domain containing tyrosine kinases which are critical for initiation of  
20  
21 signaling cascades. GPVI is the major collagen receptor on platelets. Through association  
22  
23 with the Fc receptor  $\gamma$  (FcR $\gamma$ ) chain, which contains two YxxL motifs, signal transduction is  
24  
25 initiated demonstrating that the GPVI-FcR $\gamma$  complex is essential for GPVI signaling [5].  
26  
27  
28  
29

30  
31 Other ITAM receptors of C-type lectin-like receptor (CLR) family such as dendritic cell-  
32  
33 associated C-type lectin-2 (Dectin-2) which is predominantly expressed in myeloid cells is  
34  
35 also known to interact with FcR $\gamma$  and signal through the YxxL sequences in FcR $\gamma$ .  
36  
37  
38

39  
40 GPVI/FcR $\gamma$  is the only ITAM receptor expressed in mouse platelets, but human platelets  
41  
42 express both GPVI/FcR $\gamma$  and Fc $\gamma$ RIIA both of which signal through a tandem YxxL  
43  
44 sequences. Platelet ITAM receptors utilize the same family of signaling proteins as ITAM  
45  
46 receptors in other hematopoietic cells such as T cell receptor (TCR) and B cell receptor  
47  
48 (BCR). GPVI uses predominantly Lyn and Syk and the PLC $\gamma$ 2 isoform, whereas the TCR  
49  
50 uses leukocyte-specific kinase (Lck) and zeta-chain-associated protein kinase 70 (Zap-70)  
51  
52 and the PLC $\gamma$ 1 isoform. Because of these similarities, it is possible to study the signaling  
53  
54 pathways of the platelet ITAM receptors by transfecting platelet signaling proteins into T  
55  
56 and B cell lines.  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3.1. GPVI

GPVI is a platelet-specific collagen receptor that is expressed on the platelet surface. Genetic deletion of GPVI in mice abolished the platelet response to collagen but the mice only exhibited a mild defect in haemostasis [6, 7]. Similarly, patients with a GPVI defect only show mild bleeding disorders [8, 9]. GPVI has two extracellular Ig domains, a mucin-rich stalk and short cytoplasmic domain. The cytosolic tail of GPVI has a sequence for binding to calmodulin and one that binds to the SH3 domain of Src family kinases such as Fyn and Lyn. It is non-covalently associated with the FcR $\gamma$ -chain homodimer, which contains an ITAM. Both GPVI and FcR $\gamma$  are essential for collagen-induced platelet activation [5]. Once phosphorylated on two conserved tyrosines after GPVI engagement by collagen, the FcR $\gamma$  chain is responsible for signal transduction. Phosphorylation of FcR $\gamma$  chain leads to binding of the tyrosine kinase Syk, inducing downstream signaling cascades, which are similar to those of other immune receptors as described above[10]. FcR $\gamma$  is also used by other ITAM receptors in the C-type lectin-like receptors such as Dectin-2 and MINCLE. In these cases, activation of Syk, PLC $\delta$ , CARD9-Bcl10-Malt-1 and MAPK pathways induce cytokine production in myeloid cells which is important for host defence [11]. However, these cell surface receptors including Dectin-2 are not expressed in platelets and thus the role of CARD9-Bcl10-Malt-1 pathway downstream of GPVI and C-type lectin-like receptor stimulation in platelets is unknown.

Collagen is a powerful activator of platelets that activate both GPVI and integrin  $\alpha$ 2 $\beta$ 1. A number of GPVI-specific ligands have been used to delineate the signaling pathways, including collagen-related peptide (CRP), which contains GPVI recognition motif GPO



1  
2  
3  
4  
5  
6  
7 (glycine-proline-hydroxyproline); GPVI-specific antibodies; and the snake venom toxin  
8  
9 convulxin [12].

### 10 11 12 13 14 **3.2. Fcγ Receptor IIA (FcγRIIA)**

15  
16 FcγRIIA is the second ITAM receptor in human platelets. Unlike GPVI, FcγRIIA has its  
17  
18 ITAM within its cytoplasmic tail. Since mouse platelets lack a gene equivalent to FcγRIIA,  
19  
20 transgenic mice expressing human FcγRIIA have been generated. Mouse platelets  
21  
22 expressing human FcγRIIA have enhanced spreading on fibrinogen and thrombus  
23  
24 formation in vivo, and it has been proposed that this is due to enhanced integrin outside-in  
25  
26 signaling [13]. FcγRIIA signals through the same pathways as GPVI; therefore, in this  
27  
28 commentary we will focus on the signaling through GPVI as an ITAM receptor.  
29  
30  
31  
32  
33  
34

## 35 **4. Platelet hemITAM receptors**

36  
37 The C-type lectin-like receptor CLEC-2 (encoded by the *Clec1b* gene), and the closely  
38  
39 related receptor, Dectin-1 which is found on dendritic cells, are founder members of a novel  
40  
41 class of signaling receptors defined by a single YxxL sequence and known as a hemITAM  
42  
43 (ITAM-like) receptor. CLEC-2 is the only hemITAM receptor in platelets.  
44  
45  
46  
47  
48  
49

### 50 **4.1. CLEC-2**

51  
52 CLEC-2 is a C-type lectin-like receptor that is highly expressed in platelets and to a lesser  
53  
54 extent, in other cell types such as activated dendritic cells and B cells [14]. The first ligand  
55  
56 to be identified for CLEC-2 was rhodocytin, which was purified from the Malayan pit viper,  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 *Calloselama rhodostoma*, by the groups of Huang [15] and Morita [16] in the 1990s. To  
8  
9 date, the only endogenous ligand found for CLEC-2 is podoplanin. Podoplanin is a  
10  
11 sialomucin-like glycoprotein expressed in a variety of cells but is absent from vascular  
12  
13 endothelial cells and is ordinarily not expressed in the vasculature.  
14  
15

16  
17 In vitro studies have shown that treating platelets with CLEC-2 agonists activate platelets,  
18  
19 inducing aggregation and secretion, identifying CLEC-2 as a platelet activating receptor  
20  
21 [17]. We and others have previously shown using murine models that homozygous loss of  
22  
23 CLEC-2 results in developmental defects in brain vasculature, lung inflation and  
24  
25 lymphatics, and is associated with perinatal lethality [18, 19]. However, the role of CLEC-2  
26  
27 in haemostasis and thrombus formation seems to be limited; CLEC-2-deficient mice show  
28  
29 no or minimal elongation of tail bleeding times which is also seen in GPVI-deficient mice  
30  
31 [19, 20]. These data indicate that mechanisms independent of CLEC-2 and GPVI mediate  
32  
33 platelet activation or that platelet activation by other agonists such as thrombin and ADP  
34  
35 are sufficient to form haemostatic clots in the tail.  
36  
37  
38  
39  
40  
41

42 More recently, Herzog et al. showed that platelet CLEC-2 is important for maintaining high  
43  
44 endothelial venule (HEV) barrier function during chronic inflammation [21]. Through  
45  
46 interaction with podoplanin expressing-fibroblastic reticular cells, CLEC-2 dependent  
47  
48 pathways were required to prevent vascular leak in HEV in reactive lymph nodes.  
49  
50

51 Moreover, CLEC-2 has been reported to be involved in capturing HIV-1 virus particles and  
52  
53 transferring of HIV-1 infection by platelets together with other receptors [22]. This is the  
54  
55 only report implicating CLEC-2 in pathogen recognition. It would be interesting to  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 speculate whether CLEC-2 plays a more general role in pathogen recognition since the  
8  
9 structurally related receptor Dectin-1 is a known pattern recognition receptor (PRR). This  
10  
11 family of proteins serve as protection against fungi recognising conserved microbial  
12  
13 structures known as pathogen associated molecular patterns (PAMPs) leading to the  
14  
15 activation of transcription factor nuclear factor-kappa B (NF- $\kappa$ B). Taken together these  
16  
17 reports suggest CLEC-2 has a number of roles which are not related to haemostasis.  
18  
19  
20  
21

## 22 **5. Comparison of ITAM and hemITAM receptors in platelets**

23  
24  
25 From the studies detecting signaling events and proteomic analysis it has been revealed that  
26  
27 the CLEC-2 shares many of its signaling cascades with GPVI and signals through  
28  
29 activation of Syk, Src and PLC $\gamma$ 2 using adaptor proteins such as LAT and SH2-containing  
30  
31 leukocyte protein of 76kDa (SLP-76) [23]. Moreover, in vivo experiments on GPVI/CLEC-  
32  
33 2-double knockout mice indicated that loss of both receptors resulted in severe defects in  
34  
35 haemostasis and arterial thrombus formation, whereas deletion of GPVI or CLEC-2 alone  
36  
37 only resulted in a minor or negligible defect in haemostasis and thrombus stability. This  
38  
39 suggests that there is considerable redundancy in the function of these two receptors in  
40  
41 these events [24].  
42  
43  
44  
45  
46  
47

48 Common signaling pathways in ITAM and hemITAM receptors in platelets are illustrated  
49  
50 in Fig. 1. Upon ITAM and hemITAM receptor stimulation, the tyrosine residue in the YxxL  
51  
52 motifs in both receptors becomes phosphorylated enabling Syk to bind through its two SH2  
53  
54 domains and undergo both autophosphorylation and further phosphorylation by Src family  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 kinases [25]. These events occur after a delay of 10 seconds upwards after receptor  
8  
9 stimulation.

10  
11  
12 The next step in the signaling cascade is recruitment and phosphorylation of LAT by  
13  
14 activated Syk. Phosphorylated LAT then serves as a platform that binds growth factor  
15  
16 receptor-bound protein-2 (Grb2), growth factor receptor-bound protein-2 adaptor  
17  
18 downstream of Shc (Gads) and PLC $\gamma$ 2. Adaptor protein SLP-76 is recruited to LAT by  
19  
20 binding to Gads or Grb2 which are critical for full activation of PLC $\gamma$ 2. PI3K is also  
21  
22 recruited to LAT and generates phosphatidylinositol (3,4,5)-triphosphate (PIP3) from  
23  
24 phosphatidylinositol (4, 5)-bisphosphate (PIP2). Adaptor proteins Vav1 and 3 have also  
25  
26 been shown to be recruited to the LAT signalosome by binding to SLP-76 and Syk to  
27  
28 mediate PLC $\gamma$ 2 activation. The binding of PLC $\gamma$ 2 to phosphorylated LAT and PIP3 on the  
29  
30 plasma membrane further stabilizes its localization to LAT. In addition, PIP3 recruits the  
31  
32 tyrosine kinases Btk and Tec which phosphorylate PLC $\gamma$ 2 leading to its activation.  
33  
34  
35 Activated PLC $\gamma$ 2 generates secondary messengers, inositol-1,4,5-triphosphate (IP3) and  
36  
37 1,2-diacylglycerol (DAG), which release Ca<sup>2+</sup> from the intracellular store and activate  
38  
39 protein kinase C (PKC), respectively. These pathways lead to a common platelet activation  
40  
41 cascade, resulting in platelet aggregation and dense granule secretion, which release the  
42  
43 positive feedback mediator ADP and TxA<sub>2</sub> formation. In addition, activation of PKC also  
44  
45 leads to activation of Raf-1/MEK/ERK pathways; however, unlike Raf-1 pathway  
46  
47 activation in Dectin-1, it is not clear if this leads to NF- $\kappa$ B activation.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 Syk signaling can also activate NF- $\kappa$ B via CARD9/Bcl10/MALT1 downstream of other  
8  
9 hemITAMs, such as Dectin-1, in myeloid cells. Although MALT1 and Bcl10 are expressed  
10  
11 in platelets, it is currently unclear if following (hem)ITAM receptor activation this  
12  
13 signaling pathway plays a direct role in platelet activation [26].  
14  
15

16  
17 Although there are similarities between GPVI and CLEC-2 signaling, there are also  
18  
19 quantitative and qualitative differences between these pathways (Fig. 2). First, GPVI uses  
20  
21 the YxxL sequences in the associated FcR $\gamma$  chain, whereas CLEC-2 uses YxxL sequence in  
22  
23 its own cytoplasmic domain. Secondly, as described above, ITAM receptors use two YxxLs,  
24  
25 whereas the hemITAM receptor CLEC-2 only has a single YxxL sequence motif. As a  
26  
27 consequence, in ITAM receptors Syk binds to two YxxLs in a single receptor, whereas in  
28  
29 hemITAM receptors, Syk binds to two phosphorylated receptors bridging them via its  
30  
31 tandem SH2 domains [27]. Thirdly, there are differences in proximal signaling events;  
32  
33 Suzuki-Inoue et al. have reported that platelets from mice deficient in SLP-76, which is an  
34  
35 adaptor protein that binds to LAT, do not respond to GPVI agonists. This is consistent with  
36  
37 the role of SLP-76 in other hematopoietic cells, including T cells where SLP-76 deficiency  
38  
39 leads to a failure in T cell development [17, 28]. However, in CLEC-2 signaling, although  
40  
41 platelets from SLP-76-deficient mice do not respond to a low concentration of CLEC-2  
42  
43 agonist, this can be overcome by adding a high concentration [17]. Similar results were  
44  
45 observed for platelets from Vav1/Vav3 double-deficient mice; they fail to respond to high  
46  
47 concentration of GPVI-specific agonist, but although unresponsive to CLEC-2 agonist at  
48  
49 low concentration, they respond normally to high concentration [17]. Taken together these  
50  
51 results demonstrate that SLP-76 and Vav1/Vav3 are essential for GPVI signaling whereas  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 the requirement of these adaptor proteins are overcome at high agonist concentrations in  
8  
9 CLEC-2 signaling. Moreover, these data may suggest that CLEC-2 may use other, as yet  
10  
11 unknown, adaptor proteins for signaling. A fourth difference is in the role of secondary  
12  
13 mediators used to reinforce platelet activation following GPVI or CLEC-2 activation.  
14  
15 Pollitt et al. reported that blocking secondary mediators such as ADP and TxA<sub>2</sub> can block  
16  
17 platelet activation at a low concentration of GPVI agonists but this is overcome at higher  
18  
19 concentrations. In contrast, under the same conditions, platelet activation through CLEC-2  
20  
21 signaling is severely inhibited, including activation of Syk and downstream signaling  
22  
23 events. This was insurmountable using high concentrations of agonists in human platelets  
24  
25 [29] but not in mouse platelets [30]. However, the exact mechanism of how these secondary  
26  
27 mediators reinforce CLEC-2 signaling is unknown and ADP or TxA<sub>2</sub> stimulation itself does  
28  
29 not activate CLEC-2. Also, in this paper, they reported that blocking actin polymerization  
30  
31 by cytochalasin D had no effect on maximum aggregation in GPVI-mediated platelet  
32  
33 activation but CLEC-2-mediated platelet activation is inhibited. These data suggest that  
34  
35 actin polymerization plays a key role in CLEC-2 signaling possibly by retaining CLEC-2  
36  
37 signaling molecules near CLEC-2 [29]. Although it is reported in T cells that actin  
38  
39 polymerization is important for immunological synapse formation, the role of actin  
40  
41 polymerization on CLEC-2-mediated adhesion to other cells has not yet been identified.  
42  
43  
44  
45  
46  
47  
48  
49  
50 These observations demonstrate that although ITAM and hemITAM signaling in platelets  
51  
52 share many signaling features, the regulation and importance of a number of signaling  
53  
54 molecules downstream of Syk differ between these receptors.  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 To date there have not been any reports describing Syk-independent signaling events that  
8  
9 occur during GPVI and CLEC-2-mediated platelet activation. This is in contrast to the  
10  
11 hemITAM receptor Dectin-1 where Raf-1 can activate NF- $\kappa$ B independent of Syk in  
12  
13 myeloid cells. Indeed, it has been reported that disruption of Syk activity completely blocks  
14  
15 platelet aggregation and secretion in response to GPVI or CLEC-2 agonists [31]. However,  
16  
17 it is noteworthy that Syk deficiency does not affect haemostasis whereas the GPVI/CLEC-2  
18  
19 double knockout mouse has a severe defect in haemostasis suggesting that a Syk  
20  
21 independent pathway may exist or that this is the consequence of loss of adhesion [24, 32].  
22  
23  
24  
25  
26  
27

## 28 **6. PI3K and Akt**

29  
30 The PI3K/Akt pathway is activated in response to various types of stimulation including  
31  
32 growth factors, cytokines, integrin, hormones and extracellular matrix (ECM) proteins; and  
33  
34 this pathway regulates a wide spectrum of cellular processes including cell cycle  
35  
36 progression and cell survival. This is illustrated by the correlation of gain of function  
37  
38 mutations in PI3K or Akt resulting in cancer development. Furthermore, inhibitory  
39  
40 mutations on the phosphatase PTEN (phosphatase and tensin homologue deleted on  
41  
42 chromosome 10), which is a negative regulator for PI3K/Akt, are also found in cancer.  
43  
44  
45  
46  
47

48  
49 PI3Ks are family of lipid kinases that in platelets are reported to be activated and regulate  
50  
51 platelet activation [33]. PI3Ks catalyze the conversion of plasma membrane lipid PIP2 to  
52  
53 PIP3. There are three families of PI3K: class I, II and III. Class I PI3Ks phosphorylate PIP2  
54  
55 to generate PIP3. They are heterodimeric proteins consisting of a catalytic subunit (p110 $\alpha$ ,  
56  
57 p110 $\beta$ , p110 $\delta$  and p110 $\gamma$ ) and a regulatory subunit. According to their catalytic subunit,  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 class I PI3Ks are further divided into class IA that is composed of p110 $\alpha$ , p110 $\beta$  and p110 $\delta$ ,  
8  
9 each associating with a SH2-containing regulatory subunit (p50, p55 or p85) that binds to  
10  
11 phosphorylated tyrosine residues in a Y(P)xxM motif. Class IB consists of one catalytic  
12  
13 subunit p110 $\gamma$  associated with a regulatory subunit (p101 and p84), which is regulated by  
14  
15 binding to G protein  $\beta\gamma$  subunits following GPCR activation. Human and mouse platelets  
16  
17 express all class I PI3Ks but express p110 $\delta$  at low level [34, 35]. Class II PI3Ks produce  
18  
19 phosphatidylinositol (3) phosphate (PI3P) from phosphatidylinositol (PI) and also  
20  
21 contribute to phosphatidylinositol (3,4) biphosphate (PI(3,4)P<sub>2</sub>) production. Three  
22  
23 monomers have been identified: ubiquitous PI3K-C2 $\alpha$  and C2 $\beta$  and the liver specific PI3K-  
24  
25 C2 $\gamma$ . Finally, in class III, the only member is vascular protein sortin 34 (Vps34) that is a PI  
26  
27 specific kinase that only generates PI3P and is ubiquitously expressed. The role of class I  
28  
29 PI3Ks have been studied in platelets, however the role of class II and III PI3Ks are not  
30  
31 known. Platelets also express PIP3 phosphatases that are known to regulate the level of  
32  
33 PIP3 by converting PIP3 back to PIP<sub>2</sub>; PTEN, SH2 domain-containing inositol  
34  
35 polyphosphatase 1 (SHIP1), and SHIP2 [33].

36  
37  
38 One of the major downstream effectors from PI3K is the serine/threonine kinase Akt (also  
39  
40 known as protein kinase B). Mouse and human platelets express all three isoforms of Akt,  
41  
42 namely Akt1, Akt2 and Akt3 [2, 36-39]. The activation of Akt is mainly mediated by PI3K,  
43  
44 generating PIP3 that recruits Akt and the other PH domain-containing proteins to the  
45  
46 plasma membrane, keeping Akt in proximity to its upstream kinases. The activity of Akt is  
47  
48 regulated through phosphorylation of two residues, Thr308 and Ser473. Phosphorylation of  
49  
50 Thr308 is mediated by phosphoinositide-dependent kinase 1 (PDK1), and phosphorylation  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7 of Ser473 is mediated by mTORC2 [40-43]. Consistent with this, platelets from PDK1-  
8  
9 deficient mice have impaired platelet activation and Akt phosphorylation only at Thr308  
10  
11 and have impaired thrombin-mediated platelet activation [42]. However, the importance of  
12  
13 phosphorylation at Ser473 is unknown in platelets since an mTORC2 inhibitor had no  
14  
15 effect on thrombin-mediated platelet activation [43]. In contrast, in other ITAM receptors  
16  
17 such as TCR, T cells from mTORC2 deficient mouse has significant reduction in  
18  
19 phosphorylation at Ser473 after stimulation and this leads to reduction in the Th2 cell  
20  
21 response such as IL-4 production suggesting that Ser473 phosphorylation is indispensable  
22  
23 for Akt activity [44].  
24  
25  
26  
27  
28  
29  
30

### 31 **7.1. PI3K in platelet activation**

32  
33 Studies on the role of PI3K in platelets have used genetically modified mice lacking PI3K  
34  
35 subsets and pharmacological approaches employing specific inhibitors for PI3Ks. Most of  
36  
37 the studies investigating the role of PI3K in platelets have used two structurally distinct  
38  
39 inhibitors, wortmannin and LY294002 that both inhibit class I and class II PI3Ks. From  
40  
41 these studies, it has been reported that PI3Ks are expressed in platelets and play an  
42  
43 important role in platelet activation in many processes by affecting  $\text{Ca}^{2+}$  mobilization,  
44  
45 aggregation and platelet spreading in response to several agonists such as collagen, CRP or  
46  
47 convulxin [45, 46], ristocetin/vWF [47], thrombin [36] and ADP [48]. However, the role of  
48  
49 each PI3K isoform differs depending on the agonist.  
50  
51  
52  
53  
54  
55

56 During GPVI signaling, it has been appreciated that PI3Ks are activated in two ways:  
57  
58 directly by GPVI signaling and indirectly via the production of secondary mediators and  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 subsequent activation of the ADP and TxA<sub>2</sub> receptors. In the presence of secondary  
8  
9 mediator inhibitors to block indirect activation of PI3Ks, and the PI3K inhibitors  
10  
11 wortmannin or LY294002, Akt phosphorylation, IP<sub>3</sub> accumulation, Ca<sup>2+</sup> elevation, P-  
12  
13 selectin expression and thrombus formation of human platelets were all suppressed  
14  
15 demonstrating that direct activation of PI3K/Akt by GPVI signaling is important for  
16  
17 platelet activation [46]. As discussed in Section 5, CLEC-2 signaling is highly dependent  
18  
19 on secondary mediators. Therefore inhibition of platelet activation secondary mediators  
20  
21 leads to an almost complete loss of CLEC-2 activation making it difficult to ascertain  
22  
23 whether direct or indirect signaling is important for PI3K activation during CLEC-2  
24  
25 signaling.  
26  
27  
28  
29

30  
31  
32 The catalytic subunit for PI3K $\alpha$ , p110 $\alpha$ , is frequently mutated in various types of cancer,  
33  
34 however its role in platelets is not well known. Using a PI3K $\alpha$  specific inhibitor, PIK-75, it  
35  
36 has been demonstrated that blocking PI3K $\alpha$  partially inhibited Akt phosphorylation after  
37  
38 GPVI stimulation [46, 49]. Moreover, it has been reported that both PI3K $\alpha$  and PI3K $\beta$  have  
39  
40 a non-redundant function under GPVI stimulation, with both isoforms being required for  
41  
42 full activation of PLC $\gamma$ 2, IP<sub>3</sub> formation, Ca<sup>2+</sup> elevation, thrombus formation and Rap1  
43  
44 activation, supporting distinct roles for both isoforms during platelet activation [46].  
45  
46  
47  
48

49  
50 PI3K $\beta$  is reported to be the major PI3K isoform regulating platelet activity downstream of  
51  
52 several platelet receptors including GPCRs, such as P2Y<sub>12</sub>, and integrins through regulation  
53  
54 of PLC activation and Ca<sup>2+</sup> elevation. Consistent with these reports, collagen-induced  
55  
56 aggregation, Ca<sup>2+</sup> elevation, Rap1 activation and thrombus formation are impaired in mice  
57  
58  
59  
60  
61

1  
2  
3  
4  
5  
6  
7 lacking the p85 $\alpha$  regulatory subunit (inhibiting class IA PI3Ks) [35] or p110 $\beta$  catalytic  
8  
9 subunit of PI3K $\beta$  [50]. This impairment of platelet activation was not regulated by the  
10  
11 function of PI3K as a scaffold protein since platelets from mice having the kinase dead  
12  
13 mutation of PI3K $\beta$  also had impaired platelet activation [51]. Studies using PI3K $\beta$  specific  
14  
15 inhibitors, TGX-221 and AZD6482, have also shown that it inhibits GPVI agonist-  
16  
17 mediated platelet activation including Ca<sup>2+</sup> elevation [46].  
18  
19  
20  
21

22 Studies to investigate the role of PI3K $\gamma$  in platelet function suggest activation of the kinase  
23  
24 is specific to ADP-induced platelet activation, with platelets from mice lacking p110 $\gamma$   
25  
26 catalytic subunit of PI3K $\gamma$  demonstrating impaired aggregation to ADP, whereas the  
27  
28 response to other agonists including collagen were normal [52].  
29  
30  
31  
32

33 PI3K $\delta$  is highly enriched in leukocytes however expression in platelets is low compared to  
34  
35 other PI3K isoforms. It has been reported that mouse platelets lacking the catalytic subunit  
36  
37 of p110 $\delta$  had slightly reduced aggregation to submaximal concentrations of CRP but had a  
38  
39 normal response to GPCR agonists and spread normally on collagen [3]. This suggests that  
40  
41 PI3K $\delta$  plays a minor role in GPVI signaling, partially reducing aggregation only at low  
42  
43 agonist concentrations. This minor role in platelet activation is in contrast to its role in  
44  
45 BCR and TCR signaling where the p110 $\delta$  kinase dead mutant markedly impaired B cell and  
46  
47 T cell maturation [53]. These studies on each PI3K isoform show that there is a distinct  
48  
49 regulation of PI3K activation between different ITAM receptors in different hematopoietic  
50  
51 cell types. The importance of each PI3K isoform in CLEC-2 signaling has not yet been  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 analyzed but it is important to investigate whether there is different dependency to that on  
8  
9 GPVI.

## 10 11 12 13 **7.2. Akt in platelets**

14  
15 As mentioned above, Akt is the main downstream effector for PI3K [7] and in most cases,  
16  
17 including GPVI signaling, the activation of Akt is amplified by secretion of ADP in  
18  
19 platelets [49, 54]. Additionally, PI3K-independent pathways of Akt regulation have been  
20  
21 reported. Akt is phosphorylated by PKC and by Ca<sup>2+</sup>/calmodulin-dependent protein kinase  
22  
23 kinase (CaMKK) in platelets; and in thrombin stimulation, early Akt phosphorylation was  
24  
25 poorly sensitive to PI3K inhibitors [36, 55]. In contrast to these reports, under GPVI  
26  
27 stimulation, treating platelets with wortmannin or LY294002 completely blocked the  
28  
29 phosphorylation of Akt with or without ADP, demonstrating that Akt activation is initiated  
30  
31 in a PI3K-dependent manner [49]. CLEC-2-mediated Akt activation is partially inhibited by  
32  
33 a PKC inhibitor, whereas wortmannin and LY294002 completely blocked phosphorylation.  
34  
35 This demonstrates that PI3K is the main upstream inducer for Akt activation in both GPVI  
36  
37 and CLEC-2 signaling, but that in CLEC-2 signaling, PKC also partially supports  
38  
39 activation of Akt by sustaining Akt phosphorylation at later timer point. It has also been  
40  
41 reported that PKC inhibition reduces Akt phosphorylation in GPVI-mediated activation  
42  
43 [49]. However, PKC inhibition also blocks ADP secretion therefore it is not clear if this is  
44  
45 due to inhibition of direct phosphorylation of Akt by PKC or indirect inhibition by loss of  
46  
47 ADP-dependent Akt phosphorylation.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 Studying the function of Akt in platelets is predominantly achieved by using mice models  
8  
9 with deletion of individual Akt isoforms. Among the genetically modified mice generated,  
10  
11 only Akt1 deficient mice demonstrated a significant defect in response to collagen.  
12  
13 Specifically, Akt1 deficiency reduced platelet aggregation and secretion after collagen  
14  
15 stimulation, with prolonged tail bleeding times suggesting deletion of Akt1 is sufficient to  
16  
17 impair haemostasis [2, 56]. In contrast, deletion of Akt2 resulted in a reduced platelet  
18  
19 response to thrombin or TxA2 but a normal respond to collagen [2, 39, 57]. An enhanced  
20  
21 defect was seen in mouse platelets lacking two Akt isoforms, accomplished by Akt2  
22  
23 knockdown in Akt1-deficient mice since the double knock-out is lethal [9, 10]. These data  
24  
25 indicate that Akt isoforms have both non-redundant and redundant roles in supporting  
26  
27 platelet activation. Of importance to this review, during collagen-mediated platelet  
28  
29 activation, Akt1 is the isoform preferentially activated and also contributes more directly to  
30  
31 haemostasis.  
32  
33  
34  
35  
36  
37  
38

39 It has been reported that Akt3 deficient mice also respond normally to collagen stimulation,  
40  
41 while having a reduced response to thrombin and TxA2 [39]. However, the role of Akt3 in  
42  
43 platelet activation is controversial with Moore et al. reporting that although Akt3 is  
44  
45 expressed in platelets, they were unable to detect activation of Akt3 after agonist  
46  
47 stimulation [37].  
48  
49  
50  
51

52 Pharmacological inhibitors for each isoform have not yet been developed however the role  
53  
54 of Akt has also been studied using the pan Akt inhibitor MK2206. It has been shown to  
55  
56 significantly suppress human platelet activation under both GPVI and CLEC-2 stimulation  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 in human platelets [37]. However, for GPVI, the Akt inhibitor did not completely block  
8  
9 platelet aggregation even at a low agonist concentration. In contrast, during CLEC-2  
10  
11 signaling, the Akt inhibitor almost completely blocked the aggregation and secretion at low  
12  
13 concentrations of agonist. These differences of Akt dependency between GPVI and CLEC-  
14  
15 2 may be attributable to CLEC-2 being highly dependent on secondary mediator signaling  
16  
17 compared to GPVI, as discussed earlier.  
18  
19  
20  
21

22 For future investigations, it would be worthwhile to study the roles of the individual Akt  
23  
24 isoforms in human platelets because it has been reported that a single-nucleotide  
25  
26 polymorphism (SNP) in Akt2 is associated with reduced P-selectin expression after CRP  
27  
28 stimulation in platelets [58]. However, the fact that Akt isoforms have a common domain  
29  
30 organization and high sequence homology makes it a challenge to develop specific  
31  
32 inhibitors for each isoform. Taken together these results using Akt isoform deficient mice  
33  
34 or pharmacological inhibitors for Akt demonstrates a role of Akt in (hem)ITAM receptor  
35  
36 mediated platelet activation. However, the precise mechanism by which Akt supports  
37  
38 platelet activation remains poorly characterized and several candidates have been suggested  
39  
40 as Akt substrates which is discussed in Section 8.  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **8. PI3K and Akt effectors in platelet activation**

51 In ITAM and hemITAM signaling, several candidates are proposed as an effector under the  
52  
53 PI3K/Akt pathway (Fig. 3). Akt is known to phosphorylate more than 100 substrates.  
54  
55 Glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) is known to be one of the main substrates for Akt in  
56  
57 a wide range of cell types. GSK3 $\beta$  is reported to be a negative regulator for platelet  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 activation, inhibitors potentiating platelet aggregation and secretion, and being developed  
8  
9 as a potential drug to treat diabetes, stroke, Alzheimer's and other diseases.  
10  
11 Phosphorylation of GSK3 at its N-terminal negative regulatory site (Ser21 and Ser9 in  
12  
13 GSK3 $\alpha$  and GSK3 $\beta$ , respectively) inhibits GSK3 $\alpha/\beta$  activation [59]. Deficiency of Akt  
14  
15 isoforms has been reported to partially inhibit GSK3 $\beta$  phosphorylation, suggesting that  
16  
17 each isoform has a redundant role in regulating GSK3 $\beta$ . Several groups have reported that  
18  
19 GSK3 $\alpha/\beta$  inhibition potentiates platelet activation. The GSK3 $\alpha/\beta$  inhibitors LiCl and  
20  
21 SB216763 have been shown to potentiate thrombin-induced platelet activation but to inhibit  
22  
23 collagen-stimulated platelet activation, suggesting an opposite role for GSK3 $\alpha/\beta$  under  
24  
25 GPCR and ITAM receptors [39, 60, 61]. Moreover, using a new specific inhibitor for  
26  
27 GSK3 $\alpha/\beta$ , CHIR-99021, Moore et al. have shown that thrombin-mediated platelet  
28  
29 activation was potentiated in inhibitor-treated platelets. This was in contrast to CRP-  
30  
31 mediated platelet activation which was unaltered, further suggesting the differential  
32  
33 regulation of platelet activation by GSK3 $\alpha/\beta$ , resulting in a negative role in thrombin  
34  
35 receptor signaling but positive or negligible role in GPVI signaling in platelets [37]. These  
36  
37 discrepant results from the studies on GPVI signaling using GSK3 $\alpha/\beta$  inhibitors which  
38  
39 show a negative or no effect in GPVI-mediated platelet activation may be due to the  
40  
41 different specificity of these inhibitors since LiCl and SB216763 inhibit GSK3 $\alpha/\beta$  and  
42  
43 several other kinases at the concentrations used in these studies [62]. Alternatively,  
44  
45 collagen may regulate GSK3 $\alpha/\beta$  downstream of integrin  $\alpha 2\beta 1$ , which is not activated by  
46  
47 CRP. In CLEC-2 signaling, the role of GSK3 $\alpha/\beta$  appears to be inhibitory and GSK3 $\alpha/\beta$   
48  
49 inhibitors potentiate platelet activation to rhodocytin.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 Another potential effector under PI3K activation is ERK (extracellular signal-regulated  
8  
9 kinase), one of the MAPKs (mitogen-activated protein kinases). A series of studies have  
10  
11 reported that, dependent on the conditions, activation of MAPK plays a minor role in  
12  
13 platelet activation by GPCRs and GPVI [63, 64]. Studies on the involvement of MAPK in  
14  
15 platelet function have been performed using pharmacological inhibitors. The MEK  
16  
17 (MAPK/ERK kinase) inhibitors U0126 and PD98059 that inhibit ERK activation have been  
18  
19 shown to inhibit platelet aggregation and secretion [64, 65]. On the other hand, Börsch-  
20  
21 Haubold et al. demonstrated that the MEK inhibitor PD98059 had no effect on platelet  
22  
23 aggregation induced by collagen [65]. This discrepancy could be explained by the  
24  
25 experimental conditions as the latter study was performed in the presence of a  
26  
27 cyclooxygenase inhibitor that blocks TxA<sub>2</sub> to counter the inhibitory effect of PD98059  
28  
29 against this class of enzyme. These results however do not rule out the possibility that ERK  
30  
31 may contribute to platelet activation by GPVI through the regulation of TxA<sub>2</sub> formation  
32  
33 (which is why ERK inhibitors had no effect under TxA<sub>2</sub> blockage). Wortmannin treatment  
34  
35 was shown to inhibit the ERK phosphorylation in collagen-stimulated platelets at a later  
36  
37 time point [66]. These observations suggest a role of PI3K in phosphorylating ERK at a  
38  
39 later time point which could sustain ERK activation and support platelet activation  
40  
41 following both GPVI and CLEC-2 stimulation.  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 In addition to activating Akt and ERK, PIP<sub>3</sub> generation by PI3K can lead to the recruitment  
52  
53 of PLC $\gamma$ 2, Btk and Tec, inducing PLC activation which is a key player in platelet activation  
54  
55 as described in Section 5 [67-69]. This inhibition of PLC activation by PI3K inhibition can  
56  
57 lead to impaired Ca<sup>2+</sup> elevation, integrin inside-out signaling and PKC activation,  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6 influencing more diverse pathways than just Akt or ERK activation. Consistent with this, it  
7  
8 has been reported that PI3K inhibitors inhibit PLC $\gamma$ 2 activation as shown by impaired Ca<sup>2+</sup>  
9  
10 elevation in LY294002 or wortmannin treated platelets after GPVI stimulation  
11  
12 demonstrating PLC $\gamma$ 2 is regulated by PI3K [45, 46].  
13  
14  
15  
16  
17

### 18 **9. PI3K/Akt pathways in human diseases and drug development**

19  
20 As mentioned above, Akt is the main downstream effector for PI3K and has been  
21  
22 demonstrated to play a role in platelet activation in (hem)ITAM receptors and haemostasis.  
23  
24 Consistent with these reports using mouse models, expression of a SNP in the Akt2  
25  
26 associated with human platelet response in a screening of 500 healthy European individuals  
27  
28 suggests a role of Akt in human thrombosis or bleeding disorders [58]. Moreover, in the  
29  
30 PI3K family, a SNP associated with PI3K $\gamma$  expression was also found to associate with  
31  
32 changes in mean platelet volume and annexin V binding [70]. These observations further  
33  
34 suggest a role for the PI3K/Akt pathway in human bleeding disorders and cardiovascular  
35  
36 diseases. However, the functional redundancy of each isoform of PI3K or Akt could make  
37  
38 it rather unlikely that a defect in a single isoform would result in the development of a  
39  
40 disease.  
41  
42  
43  
44  
45  
46  
47

48 In the regulation of ITAM and hemITAM receptors in platelets, patients lacking GPVI  
49  
50 display only a mild bleeding tendency and mice with either a GPVI or CLEC-2 deficiency  
51  
52 have only a mildly prolonged tail bleeding time and reduced thrombus stability. These  
53  
54 minor effects of GPVI and CLEC-2 on general haemostasis make them a good therapeutic  
55  
56 target for anti-thrombotics without bleeding side effects. To date, Akt seems to be a good  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 therapeutic target that is differentially involved in GPVI and CLEC-2 signaling, having a  
8  
9 partial effect on GPVI signaling and blocking CLEC-2 signaling. Moreover, molecules  
10  
11 involved in the PI3K/Akt pathway are known to be frequently mutated in cancer patients  
12  
13 [71], and cancer patients are at a high risk of developing venous thromboembolism, making  
14  
15 it essential to treat these patients with anti-thrombotic drugs. An Akt inhibitor may be ideal  
16  
17 for treating cancer patients since it has a relatively mild effect on GPVI- and CLEC-2-  
18  
19 mediated platelet activation in haemostasis and also can block development of the cancer.  
20  
21 In PI3K-regulating therapy, an inhibitor targeting PI3K $\beta$  would seem to be ideal for this  
22  
23 purpose based on the data obtained from PI3K-deficient mice and inhibitors. However, the  
24  
25 PI3K  $\beta$  inhibitor TGX-221, which has been reported to reduce adhesion to fibrinogen and  
26  
27 to reduce thrombosis in a rat injury model, had no effect on haemostasis as assessed by tail  
28  
29 bleeding time in rats [72]. Moreover, as a treatment against cancers and tumors, the pan Akt  
30  
31 inhibitor MK2206 is now in a phase 2 trial; further, combination of this inhibitor with other  
32  
33 anticancer agents such as receptor tyrosine kinase inhibitors, has been found to augment the  
34  
35 efficiency of this antitumor therapy [73].  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 **Acknowledgements**

45  
46  
47 This work has been supported by the Wellcome Trust (grant no. 088410). We thank Dr. SM  
48  
49 Jung, University of Cambridge and Dr S Lax, University of Birmingham for reading and  
50  
51 commenting on this manuscript.  
52  
53  
54  
55

#### 56 **Disclosure of Conflict of Interests**

1  
2  
3  
4  
5  
6  
7 The authors state that they have no conflict of interest.  
8  
9

## 10 **References**

- 11  
12 [1] Swieringa F, Kuijpers MJ, Heemskerk JW, van der Meijden PE. Targeting platelet  
13 receptor function in thrombus formation: the risk of bleeding. *Blood Rev.* 2014;28:9-21.  
14 [2] Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses  
15 to thrombin and collagen in AKT-1-deficient mice. *Blood.* 2004;104:1703-10.  
16 [3] Senis YA, Atkinson BT, Pearce AC, Wonerow P, Auger JM, Okkenhaug K, et al. Role  
17 of the p110delta PI 3-kinase in integrin and ITAM receptor signalling in platelets. *Platelets.*  
18 2005;16:191-202.  
19 [4] Kauskot A, Hoylaerts MF. Platelet receptors. *Handb Exp Pharmacol.* 2012:23-57.  
20 [5] Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE, Zirngibl H.  
21 Expression and function of the mouse collagen receptor glycoprotein VI is strictly  
22 dependent on its association with the FcRgamma chain. *J Biol Chem.* 2000;275:23998-  
23 4002.  
24 [6] Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, et al. GPVI-deficient  
25 mice lack collagen responses and are protected against experimentally induced pulmonary  
26 thromboembolism. *Thromb Res.* 2006;118:371-80.  
27 [7] Bender M, Hagedorn I, Nieswandt B. Genetic and antibody-induced glycoprotein VI  
28 deficiency equally protects mice from mechanically and FeCl(3) -induced thrombosis. *J*  
29 *Thromb Haemost.* 2011;9:1423-6.  
30 [8] Hermans C, Wittevrongel C, Thys C, Smethurst PA, Van Geet C, Freson K. A  
31 compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. *J*  
32 *Thromb Haemost.* 2009;7:1356-63.  
33 [9] Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in  
34 glycoprotein VI that lack both collagen-induced aggregation and adhesion. *J Clin Invest.*  
35 1989;84:1440-5.  
36 [10] Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. *Thromb Res.*  
37 2004;114:221-33.  
38 [11] Kerscher B, Willment JA, Brown GD. The Dectin-2 family of C-type lectin-like  
39 receptors: an update. *Int Immunol.* 2013;25:271-7.  
40 [12] Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor?  
41 *Blood.* 2003;102:449-61.  
42 [13] Zhi H, Rauova L, Hayes V, Gao C, Boylan B, Newman DK, et al. Cooperative  
43 integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo.  
44 *Blood.* 2013;121:1858-67.  
45 [14] Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, et al.  
46 Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type  
47 lectin receptor CLEC-2. *Immunity.* 2012;37:276-89.  
48 [15] Huang TF, Liu CZ, Yang SH. Aggretin, a novel platelet-aggregation inducer from  
49 snake (*Calloselasma rhodostoma*) venom, activates phospholipase C by acting as a  
50 glycoprotein Ia/IIa agonist. *Biochem J.* 1995;309 ( Pt 3):1021-7.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7 [16] Shin Y, Morita T. Rhodocytin, a functional novel platelet agonist belonging to the  
8 heterodimeric C-type lectin family, induces platelet aggregation independently of  
9 glycoprotein Ib. *Biochem Biophys Res Commun.* 1998;245:741-5.
- 10 [17] Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, et al. A novel  
11 Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.  
12 *Blood.* 2006;107:542-9.
- 13 [18] Finney BA, Schweighoffer E, Navarro-Nunez L, Benezech C, Barone F, Hughes CE,  
14 et al. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development.  
15 *Blood.* 2012;119:1747-56.
- 16 [19] Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, et al. Essential  
17 in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-  
18 2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of  
19 CLEC-2-deficient platelets. *J Biol Chem.* 2010;285:24494-507.
- 20 [20] Hughes CE, Navarro-Nunez L, Finney BA, Mourao-Sa D, Pollitt AY, Watson SP.  
21 CLEC-2 is not required for platelet aggregation at arteriolar shear. *J Thromb Haemost.*  
22 2010;8:2328-32.
- 23 [21] Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel JM, et al. Podoplanin  
24 maintains high endothelial venule integrity by interacting with platelet CLEC-2. *Nature.*  
25 2013;502:105-9.
- 26 [22] Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, et al. DC-  
27 SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. *J*  
28 *Virology.* 2006;80:8951-60.
- 29 [23] Parguina AF, Alonso J, Rosa I, Velez P, Gonzalez-Lopez MJ, Guitian E, et al. A  
30 detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the  
31 CLEC-2 signalosome: implications for CLEC-2 signaling regulation. *Blood.*  
32 2012;120:e117-26.
- 33 [24] Bender M, May F, Lorenz V, Thielmann I, Hagedorn I, Finney BA, et al. Combined in  
34 vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises  
35 hemostasis and abrogates arterial thrombosis in mice. *Arterioscler Thromb Vasc Biol.*  
36 2013;33:926-34.
- 37 [25] Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP. The novel Syk  
38 inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2  
39 signaling in platelets. *J Thromb Haemost.* 2009;7:1192-9.
- 40 [26] Karim ZA, Zhang J, Banerjee M, Chicka MC, Al Hawas R, Hamilton TR, et al.  
41 IkappaB kinase phosphorylation of SNAP-23 controls platelet secretion. *Blood.*  
42 2013;121:4567-74.
- 43 [27] Hughes CE, Pollitt AY, Mori J, Eble JA, Tomlinson MG, Hartwig JH, et al. CLEC-2  
44 activates Syk through dimerization. *Blood.* 2010;115:2947-55.
- 45 [28] Pivniouk V, Tsitsikov E, Swinton P, Rathbun G, Alt FW, Geha RS. Impaired viability  
46 and profound block in thymocyte development in mice lacking the adaptor protein SLP-76.  
47 *Cell.* 1998;94:229-38.
- 48 [29] Pollitt AY, Grygielska B, Leblond B, Desire L, Eble JA, Watson SP. Phosphorylation  
49 of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac.  
50 *Blood.* 2010;115:2938-46.
- 51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7 [30] Borgognone A, Navarro-Nunez L, Correia JN, Pollitt AY, Thomas SG, Eble JA, et al.  
8 CLEC-2-dependent activation of mouse platelets is weakly inhibited by cAMP but not by  
9 cGMP. *J Thromb Haemost.* 2014;12:550-9.
- 10 [31] Hughes CE, Finney BA, Koentgen F, Lowe KL, Watson SP. The N-terminal SH2  
11 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets.  
12 *Blood.* 2015;125:144-54.
- 13 [32] Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, et al.  
14 Genetic and pharmacological analyses of Syk function in alphaIIb beta3 signaling in  
15 platelets. *Blood.* 1999;93:2645-52.
- 16 [33] Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of  
17 platelet function. *Biochem Soc Trans.* 2004;32:387-92.
- 18 [34] Zhang J, Vanhaesebroeck B, Rittenhouse SE. Human platelets contain p110delta  
19 phosphoinositide 3-kinase. *Biochem Biophys Res Commun.* 2002;296:178-81.
- 20 [35] Watanabe N, Nakajima H, Suzuki H, Oda A, Matsubara Y, Moroi M, et al. Functional  
21 phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an  
22 impaired response to GP VI stimulation. *Blood.* 2003;102:541-8.
- 23 [36] Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. *J*  
24 *Biol Chem.* 2000;275:27790-8.
- 25 [37] Moore SF, van den Bosch MT, Hunter RW, Sakamoto K, Poole AW, Hers I. Dual  
26 regulation of glycogen synthase kinase 3 (GSK3)alpha/beta by protein kinase C  
27 (PKC)alpha and Akt promotes thrombin-mediated integrin alphaIIb beta3 activation and  
28 granule secretion in platelets. *J Biol Chem.* 2013;288:3918-28.
- 29 [38] Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in  
30 secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. *The*  
31 *Journal of clinical investigation.* 2004;113:441-50.
- 32 [39] O'Brien KA, Stojanovic-Terpo A, Hay N, Du X. An important role for Akt3 in platelet  
33 activation and thrombosis. *Blood.* 2011;118:4215-23.
- 34 [40] Dangelmaier C, Manne BK, Liverani E, Jin J, Bray P, Kunapuli SP. PDK1 selectively  
35 phosphorylates Thr(308) on Akt and contributes to human platelet functional responses.  
36 *Thrombosis and haemostasis.* 2014;111:508-17.
- 37 [41] Laurent PA, Severin S, Gratacap MP, Payrastre B. Class I PI 3-kinases signaling in  
38 platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.  
39 *Advances in biological regulation.* 2014;54:162-74.
- 40 [42] Chen X, Zhang Y, Wang Y, Li D, Zhang L, Wang K, et al. PDK1 regulates platelet  
41 activation and arterial thrombosis. *Blood.* 2013;121:3718-26.
- 42 [43] Moore SF, Hunter RW, Hers I. mTORC2 protein complex-mediated Akt (Protein  
43 Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets  
44 [corrected]. *J Biol Chem.* 2011;286:24553-60.
- 45 [44] Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al.  
46 The kinase mTOR regulates the differentiation of helper T cells through the selective  
47 activation of signaling by mTORC1 and mTORC2. *Nat Immunol.* 2011;12:295-303.
- 48 [45] Pasquet JM, Bobe R, Gross B, Gratacap MP, Tomlinson MG, Payrastre B, et al. A  
49 collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-  
50 kinase in human platelets. *Biochem J.* 1999;342 ( Pt 1):171-7.
- 51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7 [46] Gilio K, Munnix IC, Mangin P, Cosemans JM, Feijge MA, van der Meijden PE, et al.  
8 Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein  
9 VI-induced platelet signaling and thrombus formation. *J Biol Chem.* 2009;284:33750-62.  
10 [47] Yin H, Stojanovic A, Hay N, Du X. The role of Akt in the signaling pathway of the  
11 glycoprotein Ib-IX induced platelet activation. *Blood.* 2008;111:658-65.  
12 [48] Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, et al. Protease-activated  
13 receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP  
14 and cause human platelet aggregation independently of G(i) signaling. *Blood.*  
15 2002;99:3629-36.  
16 [49] Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, et al. Role of  
17 phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. *J*  
18 *Biol Chem.* 2009;284:33763-72.  
19 [50] Gratacap MP, Guillermet-Guibert J, Martin V, Chicanne G, Tronchere H, Gaits-  
20 Iacovoni F, et al. Regulation and roles of PI3Kbeta, a major actor in platelet signaling and  
21 functions. *Adv Enzyme Regul.* 2011;51:106-16.  
22 [51] Canobbio I, Stefanini L, Cipolla L, Ciralo E, Gruppi C, Balduini C, et al. Genetic  
23 evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-  
24 mediated signaling in platelets. *Blood.* 2009;114:2193-6.  
25 [52] Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F, et al. Resistance to  
26 thromboembolism in PI3Kgamma-deficient mice. *FASEB journal : official publication of*  
27 *the Federation of American Societies for Experimental Biology.* 2001;15:2019-21.  
28 [53] Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B  
29 and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. *Science.*  
30 2002;297:1031-4.  
31 [54] Xiang B, Zhang G, Liu J, Morris AJ, Smyth SS, Gartner TK, et al. A G(i) -  
32 independent mechanism mediating Akt phosphorylation in platelets. *J Thromb Haemost.*  
33 2010;8:2032-41.  
34 [55] Resendiz JC, Kroll MH, Lassila R. Protease-activated receptor-induced Akt activation-  
35 -regulation and possible function. *Journal of thrombosis and haemostasis : JTH.*  
36 2007;5:2484-93.  
37 [56] Stojanovic A, Marjanovic JA, Brovkovich VM, Peng X, Hay N, Skidgel RA, et al. A  
38 phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating  
39 platelet secretion and aggregation. *J Biol Chem.* 2006;281:16333-9.  
40 [57] Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in  
41 secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. *J Clin*  
42 *Invest.* 2004;113:441-50.  
43 [58] Jones CI, Bray S, Garner SF, Stephens J, de Bono B, Angenent WG, et al. A  
44 functional genomics approach reveals novel quantitative trait loci associated with platelet  
45 signaling pathways. *Blood.* 2009;114:1405-16.  
46 [59] Cohen P, Frame S. The renaissance of GSK3. *Nat Rev Mol Cell Biol.* 2001;2:769-76.  
47 [60] Barry FA, Graham GJ, Fry MJ, Gibbins JM. Regulation of glycogen synthase kinase 3  
48 in human platelets: a possible role in platelet function? *FEBS Lett.* 2003;553:173-8.  
49 [61] Li D, August S, Woulfe DS. GSK3beta is a negative regulator of platelet function and  
50 thrombosis. *Blood.* 2008;111:3522-30.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7 [62] Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity  
8 of protein kinase inhibitors: a further update. *Biochem J.* 2007;408:297-315.
- 9 [63] Toth-Zsomboki E, Oury C, Cornelissen H, De Vos R, Vermynen J, Hoylaerts MF.  
10 P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by  
11 enhancing myosin light chain kinase activation. *J Biol Chem.* 2003;278:46661-7.
- 12 [64] Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-  
13 activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-  
14 in retractile signaling pathway. *Blood.* 2009;113:893-901.
- 15 [65] Borsch-Haubold AG, Kramer RM, Watson SP. Inhibition of mitogen-activated protein  
16 kinase kinase does not impair primary activation of human platelets. *Biochem J.* 1996;318  
17 ( Pt 1):207-12.
- 18 [66] Endale M, Lee WM, Kamruzzaman SM, Kim SD, Park JY, Park MH, et al.  
19 Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired  
20 glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. *Br J*  
21 *Pharmacol.* 2012;167:109-27.
- 22 [67] Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoinositide-  
23 specific phospholipase C. *Physiol Rev.* 2000;80:1291-335.
- 24 [68] Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin  
25 homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol  
26 1,3,4,5-tetrakisphosphate binding capacity. *J Biol Chem.* 1996;271:30303-6.
- 27 [69] Yang WC, Ching KA, Tsoukas CD, Berg LJ. Tec kinase signaling in T cells is  
28 regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. *J*  
29 *Immunol.* 2001;166:387-95.
- 30 [70] Soranzo N, Rendon A, Gieger C, Jones CI, Watkins NA, Menzel S, et al. A novel  
31 variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function.  
32 *Blood.* 2009;113:3831-7.
- 33 [71] Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer.  
34 *Oncogene.* 2005;24:7455-64.
- 35 [72] Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, et al.  
36 PI 3-kinase p110beta: a new target for antithrombotic therapy. *Nat Med.* 2005;11:507-14.
- 37 [73] Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, et al. A phase 1  
38 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and  
39 trastuzumab in patients with HER2-positive solid tumors. *Breast Cancer Res.*  
40 2013;15:R110.
- 41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **Figure Legends**

53  
54  
55 **Figure 1.** (hem)ITAM receptor signaling  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 Activation of ITAM receptor (GPVI) and hemITAM receptor (CLEC-2) induces the  
8  
9 recruitment and subsequent activation of Syk. Activated Syk induces activation of signaling  
10  
11 cascades that lead to the activation of PLC $\gamma$ 2 and elevation of intracellular Ca<sup>2+</sup> level for  
12  
13 which the adaptor protein LAT serves as a platform for this signaling cascade. This leads to  
14  
15 granule secretion, integrin activation and aggregation of platelets which reinforces platelet  
16  
17 activation.  
18  
19  
20  
21  
22  
23  
24

25 **Figure 2.** Comparison of GPVI and CLEC-2 signaling  
26

27  
28 (i) ITAM receptor GPVI interacts with the covalent dimer of FcR- $\gamma$  chain, in which each  
29  
30 monomer contains an ITAM sequence. Activation of GPVI receptor leads to a one-to-one  
31  
32 interaction of FcR- $\gamma$  chain with Syk to activate Syk. The hemITAM receptor CLEC-2  
33  
34 requires two phosphorylated receptors to activate Syk. (ii) SLP-76 is essential for GPVI  
35  
36 signaling, whereas in CLEC-2 signaling, a high dose of agonist can overcome SLP-76  
37  
38 deficiency. (iii) Platelets from Vav1/Vav3 double knockout mice fail to respond to high  
39  
40 dose of GPVI agonist, whereas they respond to high dose of CLEC-2 agonist. (iv) Blocking  
41  
42 actin polymerization almost completely blocked CLEC-2-mediated platelet aggregation,  
43  
44 but it does not change the maximum aggregation in GPVI-mediated platelet aggregation.  
45  
46  
47  
48 (v) At high dose of agonist, secondary mediators are dispensable in GPVI signaling  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7 **Figure 3.** Effectors under the PI3K/Akt pathway  
8  
9

10 Activation of ITAM receptor (GPVI) and hemITAM receptor (CLEC-2) induces activation  
11 of PI3K which generates PIP3 in the plasma membrane. This induces the activation of Akt,  
12 which then phosphorylates GSK3. Inhibition of GSK3 by Akt suppresses platelet activation  
13 in GPVI signaling but potentiates activation in CLEC-2 signaling. PI3K also directly or  
14 indirectly activates MEK and ERK, supporting platelet activation. PIP3 generation by PI3K  
15 can also lead to activation of PLC $\gamma$ 2 by recruiting PLC $\gamma$ 2, Btk and Tec to the plasma  
16 membrane to induce calcium elevation, PKC and platelet activation.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 **Table 1** Overview of the receptors expressed in platelets  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Receptor	Ligand	Receptor type
PAR1 (only in human)	Thrombin, PAR1 peptide (synthetic)	G protein-coupled receptor
PAR4	Thrombin, PAR4 peptide (synthetic)	G protein-coupled receptor
P2Y <sub>1</sub>	ADP	G protein-coupled receptor
P2Y <sub>12</sub>	ADP	G protein-coupled receptor
TP	TxA <sub>2</sub> , U46619 (synthetic)	G protein-coupled receptor
GPVI	Collagen, Laminin, CRP (synthetic), Convulxin (snake toxin), JAQ1 (antibody)	Ig
$\alpha$ 2 $\beta$ 1	collagen	Integrin
$\alpha$ 6 $\beta$ 1	Laminin	Integrin
GPIb-XI-V	vWF, Ristocetin (snake toxin)	Leucine-rich
$\alpha$ Ib $\beta$ 3	Fibrinogen, vWF	Integrin
P2X <sub>1</sub>	ATP	Ca <sup>2+</sup> channel
CLEC-2	Podoplanin, Rhodocytin (snake toxin)	C type lectin-like




Figure 2





Figure 3






Figure 2 grayscale







Figure 3 grayscale





collagen, CRP, convulxin

podoplanin, rhodocytin

